PL4214202T3 - Stałe postacie inhibitora CDK4 - Google Patents
Stałe postacie inhibitora CDK4Info
- Publication number
- PL4214202T3 PL4214202T3 PL21783049.6T PL21783049T PL4214202T3 PL 4214202 T3 PL4214202 T3 PL 4214202T3 PL 21783049 T PL21783049 T PL 21783049T PL 4214202 T3 PL4214202 T3 PL 4214202T3
- Authority
- PL
- Poland
- Prior art keywords
- solid forms
- cdk4 inhibitor
- inhibitor solid
- cdk4
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fats And Perfumes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078636P | 2020-09-15 | 2020-09-15 | |
| US202163240268P | 2021-09-02 | 2021-09-02 | |
| PCT/IB2021/058320 WO2022058871A1 (en) | 2020-09-15 | 2021-09-13 | Solid forms of a cdk4 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4214202T3 true PL4214202T3 (pl) | 2025-05-19 |
Family
ID=78000744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21783049.6T PL4214202T3 (pl) | 2020-09-15 | 2021-09-13 | Stałe postacie inhibitora CDK4 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12570641B2 (pl) |
| EP (2) | EP4214202B1 (pl) |
| JP (2) | JP7260606B2 (pl) |
| KR (1) | KR20230069983A (pl) |
| CN (1) | CN116507620B (pl) |
| AU (1) | AU2021345531B2 (pl) |
| CA (1) | CA3195063A1 (pl) |
| DK (1) | DK4214202T3 (pl) |
| ES (1) | ES3022913T3 (pl) |
| FI (1) | FI4214202T3 (pl) |
| HU (1) | HUE070846T2 (pl) |
| MX (1) | MX2023003054A (pl) |
| PL (1) | PL4214202T3 (pl) |
| PT (1) | PT4214202T (pl) |
| SI (1) | SI4214202T1 (pl) |
| TW (2) | TW202334125A (pl) |
| WO (1) | WO2022058871A1 (pl) |
| ZA (1) | ZA202303655B (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| ES3022913T3 (en) | 2020-09-15 | 2025-05-29 | Pfizer | Solid forms of a cdk4 inhibitor |
| WO2023100070A1 (en) * | 2021-12-02 | 2023-06-08 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| CN119604288A (zh) | 2022-07-29 | 2025-03-11 | 辉瑞大药厂 | 用于治疗癌症的包含kat6抑制剂的给药方案 |
| US20260078114A1 (en) * | 2022-09-05 | 2026-03-19 | Tyk Medicines, Inc. | Compound used as inhibitor of cdk4 kinase and use thereof |
| WO2024201340A1 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof |
| CN120981721A (zh) | 2023-03-30 | 2025-11-18 | 辉瑞大药厂 | Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法 |
| WO2024246825A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Combinations of estrogen receptor degraders and cdk4 inhibitors |
| WO2024246824A1 (en) | 2023-06-02 | 2024-12-05 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
| WO2025104624A1 (en) | 2023-11-14 | 2025-05-22 | Pfizer Inc. | Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol |
| WO2025202854A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2025202871A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202900A1 (en) | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors for use in the treatment of mantle cell lymphoma |
| WO2026025013A2 (en) | 2024-07-26 | 2026-01-29 | Pfizer Inc. | Combination therapy using cdk4 inhibitors for cancer treatments |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| TW201105669A (en) | 2009-07-30 | 2011-02-16 | Irm Llc | Compounds and compositions as Syk kinase inhibitors |
| EP2970200A1 (en) | 2013-03-13 | 2016-01-20 | Abbvie Inc. | Pyridine cdk9 kinase inhibitors |
| CN105111191B (zh) | 2015-07-21 | 2018-06-08 | 上海皓元生物医药科技有限公司 | 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途 |
| KR102587758B1 (ko) | 2016-07-13 | 2023-10-12 | 사이로스 파마수티컬스, 인크. | 시클린-의존성 키나제 7 (cdk7)의 억제제 |
| JP6563623B1 (ja) | 2016-08-15 | 2019-08-21 | ファイザー・インク | ピリドピリミジノンｃｄｋ２／４／６阻害剤 |
| CR20200503A (es) * | 2018-04-26 | 2020-12-17 | Pfizer | Inhibidores de cinasa dependientes de ciclina |
| ES3022913T3 (en) | 2020-09-15 | 2025-05-29 | Pfizer | Solid forms of a cdk4 inhibitor |
-
2021
- 2021-09-13 ES ES21783049T patent/ES3022913T3/es active Active
- 2021-09-13 HU HUE21783049A patent/HUE070846T2/hu unknown
- 2021-09-13 EP EP21783049.6A patent/EP4214202B1/en active Active
- 2021-09-13 AU AU2021345531A patent/AU2021345531B2/en active Active
- 2021-09-13 WO PCT/IB2021/058320 patent/WO2022058871A1/en not_active Ceased
- 2021-09-13 PT PT217830496T patent/PT4214202T/pt unknown
- 2021-09-13 KR KR1020237012766A patent/KR20230069983A/ko not_active Ceased
- 2021-09-13 PL PL21783049.6T patent/PL4214202T3/pl unknown
- 2021-09-13 JP JP2021148619A patent/JP7260606B2/ja active Active
- 2021-09-13 EP EP25153633.0A patent/EP4578450A3/en active Pending
- 2021-09-13 SI SI202130288T patent/SI4214202T1/sl unknown
- 2021-09-13 US US18/245,039 patent/US12570641B2/en active Active
- 2021-09-13 DK DK21783049.6T patent/DK4214202T3/da active
- 2021-09-13 CN CN202180071477.7A patent/CN116507620B/zh active Active
- 2021-09-13 FI FIEP21783049.6T patent/FI4214202T3/fi active
- 2021-09-13 CA CA3195063A patent/CA3195063A1/en active Pending
- 2021-09-13 MX MX2023003054A patent/MX2023003054A/es unknown
- 2021-09-14 TW TW112102545A patent/TW202334125A/zh unknown
- 2021-09-14 TW TW110134168A patent/TWI809503B/zh active
-
2022
- 2022-10-27 JP JP2022172594A patent/JP7291839B2/ja active Active
-
2023
- 2023-03-16 ZA ZA2023/03655A patent/ZA202303655B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202303655B (en) | 2024-09-25 |
| FI4214202T3 (fi) | 2025-04-25 |
| EP4578450A3 (en) | 2025-07-16 |
| EP4214202B1 (en) | 2025-02-26 |
| AU2021345531A1 (en) | 2023-04-20 |
| WO2022058871A1 (en) | 2022-03-24 |
| US20230357211A1 (en) | 2023-11-09 |
| CA3195063A1 (en) | 2022-03-24 |
| AU2021345531B2 (en) | 2024-02-29 |
| HUE070846T2 (hu) | 2025-07-28 |
| JP7260606B2 (ja) | 2023-04-18 |
| KR20230069983A (ko) | 2023-05-19 |
| ES3022913T3 (en) | 2025-05-29 |
| US12570641B2 (en) | 2026-03-10 |
| MX2023003054A (es) | 2023-04-05 |
| EP4214202A1 (en) | 2023-07-26 |
| JP2022049005A (ja) | 2022-03-28 |
| TWI809503B (zh) | 2023-07-21 |
| EP4578450A2 (en) | 2025-07-02 |
| JP2022186995A (ja) | 2022-12-15 |
| PT4214202T (pt) | 2025-04-11 |
| CN116507620A (zh) | 2023-07-28 |
| SI4214202T1 (sl) | 2025-05-30 |
| BR112023004713A2 (pt) | 2023-04-18 |
| CN116507620B (zh) | 2025-11-18 |
| TW202334125A (zh) | 2023-09-01 |
| TW202216698A (zh) | 2022-05-01 |
| JP7291839B2 (ja) | 2023-06-15 |
| DK4214202T3 (da) | 2025-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4214202T3 (pl) | Stałe postacie inhibitora CDK4 | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4495113A4 (en) | KIF18A INHIBITOR | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| DK4301468T3 (da) | Fgfr3-inhibitorforbindelser | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| IL290527A (en) | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| EP4110333A4 (en) | Sos1 inhibitors | |
| LT3980417T (lt) | Prmt5 inhibitoriai | |
| DK4337652T3 (da) | NLRP3-hæmmere | |
| EP4125884A4 (en) | COMBINATIONS OF EIF4A INHIBITORS | |
| PL4363406T3 (pl) | Inhibitory inflamasomu nlrp3 | |
| PL4051688T3 (pl) | Inhibitory cd73 | |
| EP3980011C0 (en) | SARM1 HIBITORS | |
| PL4182308T3 (pl) | Pochodne pirydazynyloaminowe jako inhibitory ALK5 | |
| EP4153596A4 (en) | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | |
| DK3956322T3 (da) | Jak1-selektiv kinaseinhibitor | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP4003986A4 (en) | Inhibitor compounds | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| IL286832A (en) | Inhibitors of aldose reductase | |
| DK4229056T3 (da) | Triazolpyridinylforbindelser som kinasehæmmere |